Racura Oncology Ltd · ASX:RAC
Racura Oncology — Race Oncology — Investor Presentation (October 2025)
24 slides from Racura Oncology's investor presentation, October 2025
Slide 1: At the Heart of Cancer Care – Investor Presentation
October 2025 AT THE HEART OF CANCER CARE INVESTOR PRESENTATION 0 1 ASX: RAC | RACE ONCOLOGY LIMITED | ABN 61 149 318 749
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer A T T H E The material in this presentation has been prepared by Race Oncology Limited (ACN 149 318 749) (Company). H E A R T THIS IS NOT A PROSPECTUS This presentation is not a prospectus, product disclosure statement or disclosure document for the purposes of the Co
Slide 3: Corporate snapshot
Corporate snapshot A T T H E Race Oncology is an ASX-listed, clinical stage biopharmaceutical company with a dedicated mission to be at the H E A R T heart of cancer care. We are well funded to support our current programs. O F Race 12-month trading history C A N C E R Key Data ($A) C A R E ASX code
Slide 4: Why invest in Race Oncology?
Why invest in Race Oncology? A T T H E H E A R T Investment opportunity has fundamentally changed in recent times O F C A N C E R Clinically validated drug Improved drug - RC220 20yr composition of C A R E Used in >50 clinical trials. Reformulated for easier matter patent filed Established safety ad
Slide 5: Recent discoveries
5 5 A T T H E H E A R T O F C A N C E R C A R E recent discoveries
Slide 6: RC220 – improved (E,E)-bisantrene formulation
RC220 – improved (E,E)-bisantrene formulation A T T H E H E A R T RC220… O F C A N C E R • A new, improved formulation of (E,E)-bisantrene which is more soluble and can be delivered better & safer 1 C A R E • Preserves the PK/PD properties of the earlier & clinically validated RC110 formulation • Ha
Slide 7: Robust IP - recent patent filings
Robust IP - recent patent filings A T T H E • Race has discovered that bisantrene can exist in three isomeric forms - (E,E), (E,Z) H E A R T and (Z,Z) O F • Photoisomerisation of bisantrene not known prior to Race’s discovery C A N C E R • Only (E,E)-bisantrene has potent anticancer activity C A R E
Slide 8: Mechanism of action
A T T H E H E A R T O F C A N C E R C A R E mechanism Chemistry & Discovery of action 888
Slide 9: How does (E,E)-bisantrene work?
How does (E,E)-bisantrene work? A T T H E • G-quadruplexes (G4) are special folded structures that exist in H E A R T our DNA & RNA O F • G4 structures act like switches that control many of the C A N C E R important genes that cause or allow cancer to grow • (E,E)-bisantrene binds to and stabilizes
Slide 10: G4-binding anticancer effects
G4-binding anticancer effects A T T H E H E A R T • Race has confirmed (E,E)-bisantrene is both a DNA and RNA G4-stabiliser O F C A N C E R • All anticancer activities of (E,E)-bisantrene can be explained by G4-stabilisation C A R E • G4-targeting has multiple different downstream anticancer effects
Slide 11: MYC & Cancer
MYC & Cancer A T T H E % of major cancers with elevated MYC H E A R T activity • MYC discovered in 1982 O F • It is still considered to be ‘undruggable’ C A N C E R • No direct inhibitors in pharma pipelines C A R E • Much of protein is unstructured and difficult to target • MYC regulates expression
Slide 12: Protecting patients from their cancer treatment
protecting patients from their cancer treatment 12 12
Slide 13: Doxorubicin damages the cardiovascular system
Doxorubicin damages the cardiovascular system A T T H E H E A R T VO2peak is the ‘gold standard’ measure of cardiovascular function O F C A N C E R C A R E A VO2peak below Prevents patients Low VO2peak 18mL/kg/min leaves a performing basic daily associated with a 7-9- patient ‘functionally living ac
Slide 14: Protecting the heart from doxorubicin
Protecting the heart from doxorubicin A T T H E H E A R T No treatment (control) Doxorubicin RC220 + doxorubicin O F C A N C E R C A R E No Fibrosis (scarring) Extensive Fibrosis Minimal Fibrosis Animal studies demonstrated cardioprotection by RC220 including increased cardiac function and reduced f
Slide 15: Improving anticancer activity of doxorubicin
Improving anticancer activity of doxorubicin A T T H E RC220 shows potent cell-killing activity against a diverse range of human cancers when used alone and in H E A R T combination with doxorubicin, the most frequently used anthracycline1 O F C A N C E R 85% RC220 improves doxorubicin anticancer ac
Slide 16: Market opportunity
16 A T T H E H E A R T O F C A N C E R C A R E opportunity market
Slide 17: RC220 + doxorubicin – a growing market opportunity
RC220 + doxorubicin – a growing market opportunity A T T H E Annual revenue generic Annual revenue RC220 Annual doses of doxorubicin and H E A R T doxorubicin - 20231 cardioprotection + anti-cancer2 other anthracyclines (m)3 O F C A N C E R C A R E US$7b US$1.5b USD$100 base price/cycle USD$15,000 b
Slide 18: Clinical program
clinical program
Slide 19: Clinical pipeline
Clinical pipeline A T T H E IND Asset Indication Sites Discovery Phase 1 Phase 2 Phase 3 Comments H E A R T enabling Impressive 40% clinical Chaim Sheba O F Acute Myeloid response rate in Phase 2 RC1105 Medical Phase 2 C A N C E R Leukaemia AML trial completed in Centre, Israel June 2020 Successfull
Slide 20: RC220 Phase 1 open label cardioprotection trial
RC220 Phase 1 open label cardioprotection trial A T T H E H E A R T Part 1: Advanced solid tumour patients with potential Part 2: Anthracycline naïve solid tumour patients with potential to benefit to benefit from doxorubicin therapy from doxorubicin therapy O F C A N C E R n=15-33 patients n=20 pat
Slide 21: Milestones & highlights
milestones & highlights
Slide 22: Driving positive momentum
Driving positive momentum A T T H E Select FY25 highlights Select FY26 highlights H E A R T Professor Daniel Von Hoff appointed to Race’s Clinical Advisory Board Publication of results from Sheba Phase 2 clinical study in AML (in press) O F New Board appointed to support Race through its next phase
Slide 23: Key highlights of Race Oncology
Key highlights of Race Oncology A T T H E RC220 – derisked & clinically proven anticancer H E A R T drug offering much higher chance of success O F C A N C E R Solves a real & significant health problem – permanent damage caused by chemotherapy, C A R E RC220 builds on a major existing market of 20m
Slide 24: Contact
Contact PETE SMITH Executive Chairman JANE LOWE Investor & Media Relations +61 2 8051 3043 +61 411 117 774 peter.smith@raceoncology.com jane.lowe@irdepartment.com.au Authorised for release by CEO ASX: RAC | RACE ONCOLOGY LIMITED | ABN 61 149 318 749